Skip to main content

Table 2 Period of breast cancer follow-up after treatment to monitor the presence of recurrent metastatic diseases

From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors

Follow-up (month)

N (%)

6–12

2 (0.2%)

13–24

135 (12.5%)

25–36

198 (18.3%)

37–48

277 (25.6%)

49–60

155 (14.3%)

>  61

314 (29.0%)